Approval of tofacitinib (Xeljanz) for ulcerative colitis has been recommended by a unanimous vote of the FDA’s Gastrointestinal Drugs Advisory Committee. The JAK inhibitor is the first in its class to be recommended for adults living with moderately to severely active ulcerative colitis. The committee voted 15-0 in favour of the extension of the use of ...
FDA approves first JAK inhibitor for UC
By Nicola Garrett
9 Mar 2018